SERA PROGNOSTICS INC-A (SERA) Stock Price & Overview
NASDAQ:SERA • US81749D1072
Current stock price
The current stock price of SERA is 2.32 USD. Today SERA is up by 6.42%. In the past month the price increased by 8.46%. In the past year, price decreased by -35.88%.
SERA Key Statistics
- Market Cap
- 90.805M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -0.68
- Dividend Yield
- N/A
SERA Stock Performance
SERA Stock Chart
SERA Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to SERA. When comparing the yearly performance of all stocks, SERA is a bad performer in the overall market: 92.56% of all stocks are doing better.
SERA Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to SERA. The financial health of SERA is average, but there are quite some concerns on its profitability.
SERA Earnings
On March 18, 2026 SERA reported an EPS of -0.16 and a revenue of 10.00K. The company beat EPS expectations (17.44% surprise) and missed revenue expectations (-67.32% surprise).
SERA Forecast & Estimates
9 analysts have analysed SERA and the average price target is 5.1 USD. This implies a price increase of 119.83% is expected in the next year compared to the current price of 2.32.
For the next year, analysts expect an EPS growth of -1% and a revenue growth 447.37% for SERA
SERA Groups
Sector & Classification
SERA Financial Highlights
Over the last trailing twelve months SERA reported a non-GAAP Earnings per Share(EPS) of -0.68. The EPS increased by 31.31% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -31.32% | ||
| ROE | -42.34% | ||
| Debt/Equity | 0 |
SERA Ownership
SERA Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 14.06 | 368.645B | ||
| AMGN | AMGEN INC | 15.27 | 187.715B | ||
| GILD | GILEAD SCIENCES INC | 15.66 | 173.485B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 22.22 | 112.351B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.87 | 79.706B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 46.93 | 44.214B | ||
| INSM | INSMED INC | N/A | 31.674B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 30.229B | ||
| NTRA | NATERA INC | N/A | 29.365B | ||
| BIIB | BIOGEN INC | 10.89 | 26.496B | ||
| UTHR | UNITED THERAPEUTICS CORP | 19.74 | 25.315B | ||
| MRNA | MODERNA INC | N/A | 21.519B | ||
| INCY | INCYTE CORP | 12.25 | 19.324B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About SERA
Company Profile
Sera Prognostics, Inc. engages in the provision of personalized diagnostics to predict and manage pregnancy complications. The company is headquartered in Salt Lake City, Utah and currently employs 63 full-time employees. The company went IPO on 2021-07-15. The company has built a proteomics and bioinformatics platform to characterize the biology of pregnancy and to discover and validate key protein biomarkers found in blood that are accurate predictors of dynamic changes that occur during pregnancy. Its commercial product, the PreTRM test, is a validated, commercially available blood-based biomarker test to predict the risk of a premature delivery, also known as preterm birth. The PreTRM test is a non-invasive blood test given to a pregnant woman, carrying a single fetus, during weeks 18 through 20 of gestation that provides a prediction of the expectant mother’s risk of delivering spontaneously before 37 weeks’ gestation.
Company Info
IPO: 2021-07-15
SERA PROGNOSTICS INC-A
2749 E. Parleys Way, Suite 200
Salt Lake City UTAH US
CEO: Gregory C. Critchfield
Employees: 72
Phone: 18015050278
SERA PROGNOSTICS INC-A / SERA FAQ
What does SERA do?
Sera Prognostics, Inc. engages in the provision of personalized diagnostics to predict and manage pregnancy complications. The company is headquartered in Salt Lake City, Utah and currently employs 63 full-time employees. The company went IPO on 2021-07-15. The company has built a proteomics and bioinformatics platform to characterize the biology of pregnancy and to discover and validate key protein biomarkers found in blood that are accurate predictors of dynamic changes that occur during pregnancy. Its commercial product, the PreTRM test, is a validated, commercially available blood-based biomarker test to predict the risk of a premature delivery, also known as preterm birth. The PreTRM test is a non-invasive blood test given to a pregnant woman, carrying a single fetus, during weeks 18 through 20 of gestation that provides a prediction of the expectant mother’s risk of delivering spontaneously before 37 weeks’ gestation.
What is the current price of SERA stock?
The current stock price of SERA is 2.32 USD. The price increased by 6.42% in the last trading session.
Does SERA stock pay dividends?
SERA does not pay a dividend.
What is the ChartMill technical and fundamental rating of SERA stock?
SERA has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
How is the market expecting SERA stock to perform?
9 analysts have analysed SERA and the average price target is 5.1 USD. This implies a price increase of 119.83% is expected in the next year compared to the current price of 2.32.
Can you provide the PE ratio for SERA stock?
SERA PROGNOSTICS INC-A (SERA) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.68).
What is the expected growth for SERA stock?
The Revenue of SERA PROGNOSTICS INC-A (SERA) is expected to grow by 447.37% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.